[CAS NO. 1113-59-3] 3-Bromopyruvicacid
PRODUCTS SPECIFICATIONS [1113-59-3]
DESCRIPTION [1113-59-3]
Overview
| MDL | MFCD00002587 |
|---|---|
| Molecular Weight | 166.96 |
| Molecular Formula | C3H3BrO3 |
| SMILES | O=C(O)C(CBr)=O |
14 Publications Citing Use of MCE
- [1]Cell Death Dis. 2022 Sep 20;13(9):803.
- [2]Neurobiol Dis. 2021 Dec 29;105605.
- [3]Arch Toxicol. 2022 May 4.
- [4]Food Chem Toxicol. 2020 Dec 24;148:111926.
- [5]J Agric Food Chem. 2021 Oct 25.
- [6]Exp Cell Res. 2020 Mar 15;388(2):111876.
- [7]Fish Shellfish Immunol. 2022 Aug 3;S1050-4648(22)00414-4.
- [8]Molecules. 2022 Apr 11;27(8):2447.
- [9]J Inorg Biochem. 2022 Apr 20;233:111838.
- [10]J Inorg Biochem. 13 January 2022, 111725.
- [11]Exp Eye Res. 2022 Apr 28;220:109095.
- [12]Cell Stress Chaperones. 2022 May;27(3):273-283.
- [13]Research Square Print. posted 01 Nov, 2022
- [14]Research Square Preprint. 2021 Jun.
Summary
3-Bromopyruvate (Bromopyruvic acid) is an analogue of pyruvate and a potent hexokinase (HK)-II inhibitor with high tumor selectivity. 3-Bromopyruvate inhibits cell growth and induces apoptosis through interfering with glycolysis. 3-Bromopyruvate induces autophagy by stimulating ROS formation in breast cancer cells. Antimicrobial activities [1] [2] [3] .
In Vitro
3-Bromopyruvate enhances TRAIL-induced apoptosis in breast cancer cells
[2]
.
3-Bromopyruvate (Bromopyruvic acid), a hexokinase II inhibitor, can induce apoptosis in hepatocellular carcinoma cells by inducing endoplasmic reticulum (ER) stress
[2]
.
3-Bromopyruvate inhibits ATP generation and upregulates the expression of DR5. 3-Bromopyruvate upregulates CHOP, GRP78 and the phosphorylation of AMPK and augments TRAIL-induced Bax and caspase-3 levels
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [2]
| Cell Line: | MCF-7 and MDA-MB-231 cells |
| Concentration: | 40, 80, 160 or 320 µM |
| Incubation Time: | 24 hours |
| Result: | 3-Bromopyruvate (80 and 160 µmol/l) and TRAIL (400 ng/ml) significantly inhibited cell viability. |
In Vivo
3-Bromopyruvate (8 mg/kg; i.p.; every 4 days for 28 days) shows a synergistic antitumor effect in MCF-7 cell xenografts in nude mice [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female nude mice (BALB/c; 4-5-weeks old and 18-20 g) [2] |
| Dosage: | 8 mg/kg |
| Administration: | I.p.; every 4 days for 28 days |
| Result: | Showed antitumor efficacy in tumor xenografts. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 250 mg/mL ( 1497.36 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.9895 mL | 29.9473 mL | 59.8946 mL |
| 5 mM | 1.1979 mL | 5.9895 mL | 11.9789 mL |
| 10 mM | 0.5989 mL | 2.9947 mL | 5.9895 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (598.95 mM); Clear solution; Need ultrasonic
References
- [1] Gan L, et al. Synergistic Effect of 3-Bromopyruvate in Combination with Rapamycin Impacted Neuroblastoma Metabolism by Inhibiting Autophagy. Onco Targets Ther. 2020;13:11125-11137. Published 2020 Oct 29.
- [2] Chen Y, et al. 3 Bromopyruvate sensitizes human breast cancer cells to TRAIL induced apoptosis via the phosphorylated AMPK mediated upregulation of DR5. Oncol Rep. 2018;40(5):2435-2444.
- [3] Zhang Q, et al. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer. 2014;5(3-4):100-112.
Synonyms